PBM Reforms: House Hearing Suggests Bipartisan Consensus On Legislative Policies Has Limits
Executive Summary
There was lots of criticism of pharmacy benefit managers (and a fair amount aimed at pharmaceutical manufacturers) at the oversight hearing. However, Democrats may be more cautious about preserving the benefits PBMs provide versus the downsides in developing reforms.
You may also be interested in...
Industry CEOs Talk Drug Pricing, Value And The IRA
Value-based pricing for drugs remains largely a pipe dream in the US, industry leaders say, even as drug pricing pressure mounts.
Medicare Price Negotiation Law Fixes Face ‘Big Problem,’ Former Trump Official Says
Health policy experts and biopharma supply chain stakeholders discuss prospects for legislation reforming the Inflation Reduction Act, pharmacy benefit manager practices, and the 340B program during a recent conference.
Yet Another Bad Day For PBMs On Capitol Hill
Democrats and Republicans in the US Congress are not getting along on most topics these days. But when it comes to criticizing the pharmacy benefit management sector, they see eye-to-eye.